Abstract
Li et al. present a resource of single-cell RNA sequencing (scRNA-seq) data from the infusion products of relapsed or refractory large B cell lymphoma (rrLBCL) patients treated with standard-of-care axicabtagene ciloleucel and identify features that are significantly different between products from responders and non-responders at 3-month followup by PET/CT, an important landmark for long-term outcomes.
Copyright © 2023 Elsevier Inc. All rights reserved.
Publication types
-
Letter
-
Research Support, N.I.H., Extramural
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antigens, CD19
-
Humans
-
Immunotherapy, Adoptive / adverse effects
-
Lymphoma, Large B-Cell, Diffuse* / genetics
-
Lymphoma, Large B-Cell, Diffuse* / therapy
-
Positron Emission Tomography Computed Tomography
-
Receptors, Chimeric Antigen* / genetics
-
T-Lymphocytes
Substances
-
Receptors, Chimeric Antigen
-
Antigens, CD19